RxDoctor Payments Data

Mehran Movassaghi, MD

Urology · Santa Monica, CANPI 1154518629

Payments from drug & device makers

$60,893in general payments, 2019–2025

Across 392 payments — averaging $155.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EDAP Technomed Inc$48K
  • Procept Biorobotics Corporation$2K
  • Myriad Genetic Laboratories, Inc.$2K
  • Angiodynamics, Inc.$2K
  • Pfizer$844
  • AbbVie$709
  • plus $6K from 44 others

What the payments were for

  • Consulting fees$43,09671%
  • Travel & lodging$5,81510%
  • Food & beverage$11,72319%
  • Education$2590%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$60,893 in reported general payments places this provider in the 90th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$588,317
Medicare patients
802
Services billed
75,291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron73$65,852
GemtesaVibegron76$65,677
XyostedTestosterone Enanthate20$17,246
Tamsulosin Hcl696$9,921
CialisTadalafil33$9,242
Testosterone37$6,404
MotegrityPrucalopride Succinate11$5,735
Finasteride396$5,358
Testosterone Cypionate138$4,054
Dutasteride75$3,757
Alfuzosin Hcl ErAlfuzosin Hcl95$2,154
Celecoxib38$2,130
Oxybutynin Chloride ErOxybutynin Chloride100$1,741
Tadalafil13$1,355
Silodosin16$1,307

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$228$65,85273 claims
Sumitomo Pharma America, Inc.Gemtesa$119$65,67776 claims
Antares Pharma, Inc.Xyosted$412$17,24620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,324 urology providers in California.

Other urology in Santa Monica

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →